Giannakaki Venetia, Miyakis Spiros
The Academic Suite, Level 8, Block C, The Wollongong Hospital, Wollongong NSW 2500, Australia.
Recent Pat Antiinfect Drug Discov. 2012 Dec 1;7(3):182-8. doi: 10.2174/157489112803521959.
Antimicrobial resistance threatens to compromise the treatment of bacterial infectious diseases. Strains resistant to most (if not all) antibiotics available have emerged. Gram-positive such representatives include strains of Methicillinresistant Staphylococcus aureus (MRSA), Vancomycin-resistant Enterococci (VRE) and highly-resistant to penicillin Streptococcus pneumoniae. Although the phenomenon of antimicrobial drug resistance is expanding, limited number of new antibiotics has been successfully developed in the last few decades. Several novel antimicrobial agents, however, are currently in diverse phases of development and undergoing clinical trials. This review will summarize the main candidates for novel antibacterial agents active against Gram-positive multi-resistant pathogens along with the discussion of some patents relevant to the topic.
抗菌药物耐药性威胁到细菌感染性疾病的治疗。对大多数（甚至所有）现有抗生素耐药的菌株已经出现。革兰氏阳性菌的此类代表包括耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素肠球菌（VRE）和对青霉素高度耐药的肺炎链球菌。尽管抗菌药物耐药现象正在扩大，但在过去几十年中成功开发的新抗生素数量有限。然而，目前有几种新型抗菌剂正处于不同的开发阶段并正在进行临床试验。本综述将总结针对革兰氏阳性多重耐药病原体的新型抗菌剂的主要候选药物，并讨论一些与该主题相关的专利。
